Nextmune
Nextmune is a leading provider of niche pet pharmaceutical products and services dedicated to improving the quality of life for companion animals.
The group takes a holistic approach to allergy, offering allergy diagnostics, allergy treatment, and specialty nutraceuticals (nutrition with pharmaceutical-like effects).
The underlying trends driving the pet immunotherapy market are identified as:
Shifting Demographics, longer life expectancy and increasing number of single households lead to increasing number of pets.
Changing Social Values & Behaviour lead to a humanisation of pets, increased spending on each pet and an increased focus on health and care for pets.
Technological Advancement leads to improved treatments which increases demand for premium products.
Geographical footprint:
Nextmune has operations in Sweden, Germany, Netherlands, Norway, Spain and the US
Reach:
Grown to global
The Group expanded from its Swedish base to having a global presence, with operations across Europe and the US, selling to 70 countries world-wide.
Employees:
Grown from 20 to 90
